ArticleACS central science2020
Redox-Responsive Polycondensate Neoepitope for Enhanced Personalized Cancer Vaccine.
Article in ACS central science, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 56 citations in OpenAlex.
- Recent Review on Biological Barriers and Host-Material Interfaces in Precision Drug Delivery: Advancement in Biomaterial Engineering for Better Treatment Therapies.Pharmaceutics · 2024Review
- Design and Evaluation of Synthetic Delivery Formulations for Peptide-Based Cancer Vaccines.BME frontiers · 2024Article
- Biopolymer-Based Nanogel Approach in Drug Delivery: Basic Concept and Current Developments.Pharmaceutics · 2023Review
- Biomaterials Facilitating Dendritic Cell-Mediated Cancer Immunotherapy.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2023Review
- Well-Defined Mannosylated Polymer for Peptide Vaccine Delivery with Enhanced Antitumor Immunity.Advanced healthcare materials · 2022Article
- Generation of Tumor-Specific Cytotoxic T Cells From BloodFrontiers in oncology · 2022Article
- Chemically Tuning the Antigen Release Kinetics from Spherical Nucleic Acids Maximizes Immune Stimulation.ACS central science · 2021Article
- Lipid-Polyglutamate Nanoparticle Vaccine Platform.ACS applied materials & interfaces · 2021Article
- Engineering precision nanoparticles for drug delivery.Nature reviews. Drug discovery · 2021Review
- Derivation and Clinical Validation of a Redox-Driven Prognostic Signature for Colorectal Cancer.Frontiers in oncology · 2021Article
- Designing Nanoparticle-based Drug Delivery Systems for Precision Medicine.International journal of medical sciences · 2021Review
- Fabrication of pH/Redox Dual-Responsive Mixed Polyprodrug Micelles for Improving Cancer Chemotherapy.Frontiers in pharmacology · 2021Article
- Engineering Prodrug Nanomedicine for Cancer Immunotherapy.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2020Review
- Severe Acute Respiratory Syndrome Coronavirus-2 Spike Protein Nanogel as a Pro-Antigen Strategy with Enhanced Protective Immune Responses.Small (Weinheim an der Bergstrasse, Germany) · 2020Article
- Potent and Prolonged Innate Immune Activation by Enzyme-Responsive Imidazoquinoline TLR7/8 Agonist Prodrug Vesicles.Journal of the American Chemical Society · 2020Article
- Fusing Antigens and Adjuvants into Traceless Nanogels.ACS central science · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
A versatile and highly effective platform remains a major challenge in the development of personalized cancer vaccines. Here, we devised a redox-responsive polycondensate neoepitope (PNE) through a reversible polycondensation reaction of peptide neoantigens and adjuvants together with a tracelessly responsive linker-monomer. Peptide-based neoantigens with diverse sequences and structures could be copolymerized with molecular adjuvants to form PNEs of high loading capacity for vaccine delivery without adding any carriers. The redox-responsive PNEs with controlled molecular weights and sizes efficiently targeted and accumulated in draining lymph nodes and greatly promoted the antigen capture and cross-presentation by professional antigen presenting cells. Mice immunized with PNEs showed markedly enhanced antigen-specific T cell response and the protective immunity against the tumor cell challenge.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.